论文部分内容阅读
目的:观察氯吡格雷在急性冠状动脉综合征(ACS)中的抗炎作用。方法:入选健康对照组30例、稳定型心绞痛(SAP)组40例、ACS患者66例,后者按照治疗方案不同随机、单盲分为氯吡格雷加阿司匹林组(A组)和阿司匹林(B组),观察疗程1周。所有受检者测定入院时血浆高敏C反应蛋白(hs-CRP)和P选择素(Ps)水平,ACS患者治疗1周后复查hs-CRP和Ps。观察各组hs-CRP和Ps的基线状态及治疗后变化情况。结果:药物干预前ACSA、B组患者hs-CRP和Ps较SAP组和健康对照组明显升高(P<0.01)。而SAP组与健康对照组之间,A组和B组之间hs-CRP和Ps差异无统计学意义(P>0.05),干预1周后A组比B组hsCRP和Ps显著降低(P<0.01)。结论:ACS存在明显的炎症过程;氯吡格雷可以下调ACS患者的炎症因子,具有抗炎作用。
Objective: To observe the anti-inflammatory effect of clopidogrel in acute coronary syndrome (ACS). Methods: Thirty patients in the control group, 40 patients in stable angina pectoris group (SAP) and 66 patients in ACS group were randomly divided into clopidogrel plus aspirin group (A group) and aspirin group (B) Group), observe the course of treatment for 1 week. All subjects were tested for plasma hs-CRP and P-selectin (Ps) levels at admission, and hs-CRP and Ps were examined in ACS patients after 1 week of treatment. The baseline status of hs-CRP and Ps in each group and the changes after treatment were observed. Results: The hs-CRP and Ps in ACSA group and B group before drug intervention were significantly higher than those in SAP group and healthy control group (P <0.01). There was no significant difference between hs-CRP and Ps in SAP group and healthy control group (P> 0.05). The hsCRP and Ps in A group were significantly lower than those in B group after one week intervention (P < 0.01). Conclusion: ACS has obvious inflammatory process; clopidogrel can down-regulate inflammatory cytokines in ACS patients and has anti-inflammatory effects.